佛慈制药：公司上半年营业收入为4.29亿元

Core Viewpoint - The company is focusing on high-quality development and actively responding to changes in industry policies and market conditions, aiming to improve operational efficiency and management indicators [1] Financial Performance - In the first half of 2025, the company's operating revenue was 429 million yuan, and the net profit attributable to shareholders was 30.10 million yuan [1] - The net cash flow from operating activities was 17.88 million yuan, achieving a positive turnaround with a year-on-year growth of 364.33% [1] - The overall gross profit margin in the first half of 2025 increased compared to the entire year of 2024 [1] Strategic Initiatives - The company is committed to exploring market potential, strengthening cost control, and enhancing internal management to stabilize and improve operational management indicators [1]